Amorphous Pitolisant Solid Dispersion for Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pitolisant, a histamine H3-receptor antagonist, faces challenges in maintaining physical and chemical stability, solubility, and bioavailability due to its crystalline forms, which affect its efficacy in treating narcolepsy and cataplexy.
Innovation Solution
A pharmaceutical mixture comprising pitolisant free base or its pharmaceutically acceptable salt in amorphous form, stabilized with at least one pharmaceutically acceptable excipient, such as cyclodextrin or silica, using methods like hot-melt extrusion or spray granulation to create a solid dispersion or premix, enhancing solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If crystalline forms of pitolisant are used, then physical and chemical stability is improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent changes the physical state parameter of pitolisant from crystalline to amorphous form. This parameter change fundamentally alters the dissolution behavior and solubility characteristics while maintaining stability through specific formulation approaches. The amorphous form provides higher solubility and bioavailability compared to crystalline forms.
Solution Approach 2:
The patent creates a composite pharmaceutical composition by combining amorphous pitolisant with specific excipients and carriers. This composite approach allows the amorphous drug substance to be stabilized while maintaining its enhanced solubility properties, effectively resolving the contradiction between stability and solubility.
2Reliability
If amorphous form of pitolisant is used, then solubility and bioavailability are improved, but physical and chemical stability deteriorates
Solution Approach 1:
The patent introduces excipients and carriers as intermediary substances that stabilize the amorphous pitolisant. These intermediaries prevent unwanted physical and chemical transformations of the amorphous drug substance while allowing it to maintain its superior solubility and bioavailability characteristics.
Solution Approach 2:
The patent modifies the environmental parameters (such as moisture content, temperature, and pH) through careful formulation design. By controlling these parameters, the amorphous pitolisant remains stable in the pharmaceutical composition while retaining its enhanced dissolution properties.
3Ease of manufacture
If crystalline pitolisant hydrochloride is used, then manufacturing stability is improved, but dissolution behaviour and solubility deteriorate
Solution Approach 1:
The patent changes the physical form parameter from crystalline to amorphous during the manufacturing process. This parameter change is achieved through controlled processing conditions that prevent crystallization while maintaining manufacturing feasibility and product stability.
Solution Approach 2:
The patent utilizes phase transition from crystalline to amorphous state during formulation processing. This phase transition is controlled through specific processing conditions (such as drying, milling, or melting) that convert the crystalline drug substance into an amorphous form with improved dissolution behavior.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous form of pitolisant in the pharmaceutical mixture achieves improved physical and chemical stability, high solubility, and bioavailability, facilitating effective formulation into oral dosage forms for treating narcolepsy and cataplexy.
Implementation Method 1
pitolisant free base or a pharmaceutically acceptable salt thereof is present in the mixture in amorphous form
Implementation Method 2
the chemical and physical stability of a drug are dependent on the solid state. Quite often, metastable crystalline or amorphous forms of a drug have to be stabilized in the pharmaceutical composition in order to prevent chemical degradation and interconversion
Data Source
AI summary
The present invention relates to a pharmaceutical mixture comprising amorphous pitolisant free base or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The present invention also related to an oral dosage form containing the pharmaceutical mixture and a method for treating narcolepsy with or without cataplexy.